BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 8, 2025
See today's BioWorld
Home
» Portola turns to FDA for antidote to Andexxa CRL
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Portola turns to FDA for antidote to Andexxa CRL
Aug. 19, 2016
By
Michael Fitzhugh
No Comments
An FDA complete response letter (CRL) for Portola Pharmaceuticals Inc.'s factor Xa inhibitor antidote, Andexxa (andexanet alfa), left the company "significantly surprised," said CEO Bill Lis.
BioWorld
